Psychoplastogen
Psychoplastogens are a group of
Etymology and nomenclature
The term psychoplastogen comes from the Greek roots psych- (mind), -plast (molded), and -gen (producing) and covers a variety of chemotypes and receptor targets. It was coined by David E. Olson in collaboration with Valentina Popescu, both at the University of California, Davis.[3]
The term neuroplastogen is sometimes used as a synonym for psychoplastogen, especially when speaking to the biological substrate rather than the therapeutic.
Chemistry
Psychoplastogens come in a variety of chemotypes but, by definition, are small molecules.[1]
Pharmacology
Psychoplastogens exert their effects by promoting structural and functional neural plasticity through diverse targets including, but not limited to, 5-HT2A, NMDA, and muscarinic receptors. Some are biased agonists. While each compound may have a different receptor binding profile, signaling appears to converge at the tyrosine kinase B (TrkB) and mammalian target of rapamycin (mTOR) pathways.[3][4] Convergence at TrkB and mTOR parallels that of traditional antidepressants with known efficacies, but with more rapid onset.[5]
Due to their rapid and sustained effects, psychoplastogens could potentially be dosed intermittently.[6]
In addition to the neuroplasticity effects, these compounds can have other epiphenomena including sedation, dissociation, and hallucinations.[6]
Approved medical uses
Several psychoplastogens have either been approved or are in development for the treatment of a variety of brain disorders associated with neuronal atrophy where neuroplasticity can elicit beneficial effects.[6]
Esketamine, sold under the brand name Spravato and produced by Janssen Pharmaceuticals, was approved by the FDA in March 2019 for the treatment of Treatment-Resistant Depression (TRD) and suicidal ideation.[7] As of 2022, it is the only psychoplastogen approved in the US for the treatment of a neuropsychiatric disorder.[6] Esketamine is the S(+) enantiomer of ketamine and functions as an NMDA receptor antagonist.[8]
Clinical development
Other psychoplastogens that are being investigated in the clinic include:
- MDMA-assisted psychotherapy is being investigated for treatment of PTSD. A recent placebo controlled Phase 3 trial found that 67% of participants in the MDMA+therapy group no longer met the diagnostic criteria for PTSD whereas 32% of those in the placebo+therapy group no longer met PTSD threshold.[9] MDMA-assisted psychotherapy is also currently in Phase 2 trials for eating disorders,[10] anxiety associated with life-threatening illness,[11] and social anxiety in autistic adults.[12]
- psilocybin mushrooms that serves as a prodrug for psilocin, is currently being investigated in clinical trials of Hallucinogen-Assisted Therapy for a variety of neuropsychiatric disorders. To date studies have explored the utility of psilocybin in a variety of diseases, including TRD,[13][14] smoking addiction,[15][16] and anxiety and depression in people with cancer diagnoses.[17]
- LSD is being tested in phase 2 trials for cluster headaches and anxiety.[18]
- DMT is being studied for depression.[19]
- 5-MeO-DMT is being studied for depression and eating disorders.[20]
- Ibogaine and Noribogaine are being studied for addiction.[21][22][23]
List of known psychoplastogens
- Tryptamines: Psilocin, DMT, 5-MeO-DMT
- LSD
- Amphetamines: DOI, MDMA
- Iboga: Ibogaine, Noribogaine
- Tabernanthalog
- AAZ-A-154
- Ketamine
- Scopolamine
- Rapastinel
See also
References
- ^ PMID 30262987.
- PMID 32150976.
- ^ PMID 29898390.
- PMID 23751205.
- PMID 33312794.
- ^ PMID 34671279.
- ^ Office of the Commissioner (2020-03-24). "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic". U.S, Food and Drug Adminitartion. Retrieved 2021-08-26.
- ^ Olympic Behavioral Health
- PMID 33972795.
- ^ Clinical trial number NCT04454684 for "An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders" at ClinicalTrials.gov
- ^ Clinical trial number NCT02427568 for "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illnes" at ClinicalTrials.gov
- ^ Clinical trial number NCT02008396 for "A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults" at ClinicalTrials.gov
- PMID 29030624.
- ^ Clinical trial number NCT05029466 for "The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study" at ClinicalTrials.gov
- PMID 27441452.
- ^ Clinical trial number NCT01943994 for "Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study" at ClinicalTrials.gov
- PMID 27909165.
- ^ Clinical trial number NCT03781128 for "Safety and Efficacy of Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache: a Randomized, Double-blind, Placebo-controlled Phase II Study" at ClinicalTrials.gov
- PMID 35064294.
- PMID 30822141.
- ^ Parkins K (10 March 2021). "DemeRx and Atai get MHRA nod to start trial of ibogaine for opioid use disorder". Clinical Trials Arena. Retrieved 2022-05-11.
- PMID 30272050.
- ^ "Ibogaine Use in Addiction Treatment: An Overview". INN. 2022-02-23. Retrieved 2022-05-11.